A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North central cancer treatment group study N0528

Alex Adjei, Grace K. Dy, Sumithra J Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, Helen J Ross, Rafat H. Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R Molina

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

INTRODUCTION: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced non-small-cell lung cancer. METHODS: A lead-in phase to determine the tolerability of gemcitabine 1000 mg/m on days 1 and 8, and carboplatin on day 1 at area under curve 5 administered every 21 days with cediranib 45 mg once daily was followed by a 2 (A):1 (B) randomized phase II study. The primary end point was confirmed overall response rate (ORR) with 6-month progression-free survival (PFS6) rate in arm A as secondary end point. Polymorphisms in genes encoding cediranib targets and transport were correlated with treatment outcome. RESULTS: On the basis of the safety assessment, cediranib 30 mg daily was used in the phase II portion. A total of 58 and 29 evaluable patients were accrued to arms A and B. Patients in A experienced more grade 3+ nonhematologic adverse events, 71% versus 45% (p = 0.01). The ORR was 19% (A) versus 20% (B) (p = 1.0). PFS6 in A was 48% (95% confidence interval: 35%-62%), thus meeting the protocol-specified threshold of at least 40%. The median overall survival was 12.0 versus 9.9 months (p = 0.10). FGFR1 rs7012413, FGFR2 rs2912791, and VEGFR3 rs11748431 polymorphisms were significantly associated with decreased overall survival (hazard ratio 2.78-5.01, p = 0.0002-0.0095). CONCLUSIONS: The trial did not meet its primary end point of ORR but met its secondary end point of PFS6. The combination with cediranib 30 mg daily resulted in increased toxicity. Pharmacogenetic analysis revealed an association of FGFR and VEGFR variants with survival.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalJournal of Thoracic Oncology
Volume8
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

gemcitabine
Carboplatin
Non-Small Cell Lung Carcinoma
Neoplasms
Survival
Therapeutics
Safety
Disease-Free Survival
Area Under Curve
Survival Rate
cediranib
Confidence Intervals

Keywords

  • Carboplatin
  • Cediranib
  • Gemcitabine

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer : North central cancer treatment group study N0528. / Adjei, Alex; Dy, Grace K.; Mandrekar, Sumithra J; Nelson, Garth D.; Meyers, Jeffrey P.; Adjei, Araba A.; Ross, Helen J; Ansari, Rafat H.; Lyss, Alan P.; Stella, Philip J.; Schild, Steven E.; Molina, Julian R.

In: Journal of Thoracic Oncology, Vol. 8, No. 1, 01.2013, p. 79-88.

Research output: Contribution to journalArticle

@article{7c529bde1032427ab71793c57561b738,
title = "A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North central cancer treatment group study N0528",
abstract = "INTRODUCTION: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced non-small-cell lung cancer. METHODS: A lead-in phase to determine the tolerability of gemcitabine 1000 mg/m on days 1 and 8, and carboplatin on day 1 at area under curve 5 administered every 21 days with cediranib 45 mg once daily was followed by a 2 (A):1 (B) randomized phase II study. The primary end point was confirmed overall response rate (ORR) with 6-month progression-free survival (PFS6) rate in arm A as secondary end point. Polymorphisms in genes encoding cediranib targets and transport were correlated with treatment outcome. RESULTS: On the basis of the safety assessment, cediranib 30 mg daily was used in the phase II portion. A total of 58 and 29 evaluable patients were accrued to arms A and B. Patients in A experienced more grade 3+ nonhematologic adverse events, 71{\%} versus 45{\%} (p = 0.01). The ORR was 19{\%} (A) versus 20{\%} (B) (p = 1.0). PFS6 in A was 48{\%} (95{\%} confidence interval: 35{\%}-62{\%}), thus meeting the protocol-specified threshold of at least 40{\%}. The median overall survival was 12.0 versus 9.9 months (p = 0.10). FGFR1 rs7012413, FGFR2 rs2912791, and VEGFR3 rs11748431 polymorphisms were significantly associated with decreased overall survival (hazard ratio 2.78-5.01, p = 0.0002-0.0095). CONCLUSIONS: The trial did not meet its primary end point of ORR but met its secondary end point of PFS6. The combination with cediranib 30 mg daily resulted in increased toxicity. Pharmacogenetic analysis revealed an association of FGFR and VEGFR variants with survival.",
keywords = "Carboplatin, Cediranib, Gemcitabine",
author = "Alex Adjei and Dy, {Grace K.} and Mandrekar, {Sumithra J} and Nelson, {Garth D.} and Meyers, {Jeffrey P.} and Adjei, {Araba A.} and Ross, {Helen J} and Ansari, {Rafat H.} and Lyss, {Alan P.} and Stella, {Philip J.} and Schild, {Steven E.} and Molina, {Julian R}",
year = "2013",
month = "1",
doi = "10.1097/JTO.0b013e318274a85d",
language = "English (US)",
volume = "8",
pages = "79--88",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

TY - JOUR

T1 - A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer

T2 - North central cancer treatment group study N0528

AU - Adjei, Alex

AU - Dy, Grace K.

AU - Mandrekar, Sumithra J

AU - Nelson, Garth D.

AU - Meyers, Jeffrey P.

AU - Adjei, Araba A.

AU - Ross, Helen J

AU - Ansari, Rafat H.

AU - Lyss, Alan P.

AU - Stella, Philip J.

AU - Schild, Steven E.

AU - Molina, Julian R

PY - 2013/1

Y1 - 2013/1

N2 - INTRODUCTION: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced non-small-cell lung cancer. METHODS: A lead-in phase to determine the tolerability of gemcitabine 1000 mg/m on days 1 and 8, and carboplatin on day 1 at area under curve 5 administered every 21 days with cediranib 45 mg once daily was followed by a 2 (A):1 (B) randomized phase II study. The primary end point was confirmed overall response rate (ORR) with 6-month progression-free survival (PFS6) rate in arm A as secondary end point. Polymorphisms in genes encoding cediranib targets and transport were correlated with treatment outcome. RESULTS: On the basis of the safety assessment, cediranib 30 mg daily was used in the phase II portion. A total of 58 and 29 evaluable patients were accrued to arms A and B. Patients in A experienced more grade 3+ nonhematologic adverse events, 71% versus 45% (p = 0.01). The ORR was 19% (A) versus 20% (B) (p = 1.0). PFS6 in A was 48% (95% confidence interval: 35%-62%), thus meeting the protocol-specified threshold of at least 40%. The median overall survival was 12.0 versus 9.9 months (p = 0.10). FGFR1 rs7012413, FGFR2 rs2912791, and VEGFR3 rs11748431 polymorphisms were significantly associated with decreased overall survival (hazard ratio 2.78-5.01, p = 0.0002-0.0095). CONCLUSIONS: The trial did not meet its primary end point of ORR but met its secondary end point of PFS6. The combination with cediranib 30 mg daily resulted in increased toxicity. Pharmacogenetic analysis revealed an association of FGFR and VEGFR variants with survival.

AB - INTRODUCTION: The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced non-small-cell lung cancer. METHODS: A lead-in phase to determine the tolerability of gemcitabine 1000 mg/m on days 1 and 8, and carboplatin on day 1 at area under curve 5 administered every 21 days with cediranib 45 mg once daily was followed by a 2 (A):1 (B) randomized phase II study. The primary end point was confirmed overall response rate (ORR) with 6-month progression-free survival (PFS6) rate in arm A as secondary end point. Polymorphisms in genes encoding cediranib targets and transport were correlated with treatment outcome. RESULTS: On the basis of the safety assessment, cediranib 30 mg daily was used in the phase II portion. A total of 58 and 29 evaluable patients were accrued to arms A and B. Patients in A experienced more grade 3+ nonhematologic adverse events, 71% versus 45% (p = 0.01). The ORR was 19% (A) versus 20% (B) (p = 1.0). PFS6 in A was 48% (95% confidence interval: 35%-62%), thus meeting the protocol-specified threshold of at least 40%. The median overall survival was 12.0 versus 9.9 months (p = 0.10). FGFR1 rs7012413, FGFR2 rs2912791, and VEGFR3 rs11748431 polymorphisms were significantly associated with decreased overall survival (hazard ratio 2.78-5.01, p = 0.0002-0.0095). CONCLUSIONS: The trial did not meet its primary end point of ORR but met its secondary end point of PFS6. The combination with cediranib 30 mg daily resulted in increased toxicity. Pharmacogenetic analysis revealed an association of FGFR and VEGFR variants with survival.

KW - Carboplatin

KW - Cediranib

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=84871977845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871977845&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318274a85d

DO - 10.1097/JTO.0b013e318274a85d

M3 - Article

C2 - 23232491

AN - SCOPUS:84871977845

VL - 8

SP - 79

EP - 88

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -